As the field surges with clinical and commercial momentum, from Sanofi’s continued success with Dupixent, Corvus' promising Phase 1 data on Soquelitinib, and landmark M&A deals like Gilead’s $1.7B inflammation partnership with LEO Pharma, the 9th Dermatology Drug Development Summit returns to unite 120+ leading experts committed to solving the most pressing R&D bottlenecks in dermatology drug development.

Join industry leaders this November, to explore disease heterogeneity, novel therapies and MoA, safety and the evolving reg landscape, as well as deep dives into the latest preclinical and clinical findings across rare and common disease (including AD, Psoriasis, HS, Vitiligo, Pemphigus Nodularis, Bullous Pemphigoid, Alopecia Areata).

From bispecifics to oligos, discover the modalities reshaping derma pipelines and hear insights from AbbVie, Sanofi, Takeda, Incyte, Merck, and others across discovery, preclinical, translational, clinical, and medical affairs.